ReviewComputational and structural biotechnology journal2026
Longitudinal omics data analysis: approaches and applications.
Review in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Enhancing Omics Analyses Through Coalitional Games and Shapley Values.Methods and protocols · 2026Article
- Proteomic signals are not equal clinical phenotypes: redefining evidence standards in arbovirus-SARS-CoV-2 cross-reactivity.Frontiers in immunology · 2026Review
- Programming the tumor microenvironment through microbiome-driven mechanisms.Frontiers in cellular and infection microbiology · 2026Review
- Remimazolam versus propofol on seizure adequacy in electroconvulsive therapy: a retrospective cohort study.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Longitudinal omics data (LOD) analysis is essential for understanding the dynamics of biological processes and disease progression over time. This review explores various statistical and computational approaches for analyzing such data, emphasizing their applications and limitations. The main characteristics of longitudinal data, such as imbalance, high-dimensionality, and non-Gaussianity are discussed for modeling and hypothesis testing. We discuss the properties of linear mixed models (LMM) and generalized linear mixed models (GLMM) as foundational tools in LOD analyses and highlight their extensions to handle the obstacles in the frequentist and Bayesian frameworks. We differentiate dynamic data analysis between time-course and longitudinal analyses, covering functional data analysis (FDA) and replication constraints. We explore classification techniques, single-cell studies as exemplary omics longitudinal studies, survival modeling, and multivariate methods for clinical/biomarker-based applications. Emerging topics, including data integration, clustering, and network-based modeling, are also discussed. We categorize the state-of-the-art approaches applicable to omics data, highlighting how they address the data features. This review serves as a guideline for researchers seeking robust strategies to analyze LOD effectively, which is usually complex.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.